Evidence map›Paper›PMID 36446586›Full record

ArticleThe Journal of neuroscience : the official journal of the Society for Neuroscience2023

Radiogenomics of

Luke W Bonham, Ethan G Geier, Daniel W Sirkis, Josiah K Leong, Eliana Marisa Ramos, Qing Wang, Anna Karydas, Suzee E Lee, Virginia E Sturm, Russell P Sawyer and 15 more

Open access · hybridAbstract read
In one paragraph

Article in The Journal of neuroscience : the official journal of the Society for Neuroscience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. LINE-1 Retrotransposons and Amyotrophic Lateral Sclerosis.International journal of molecular sciences · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Frontiers in neuroscience · 2024
    Article
  8. Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 7 institutions in 2 countries.

Luke W BonhamMemory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, California 94158.
Ethan G GeierMemory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, California 94158.
Daniel W SirkisMemory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, California 94158.ORCID 0000-0003-3440-8859
Josiah K LeongMemory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, California 94158.
Eliana Marisa RamosDepartment of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California 90095.
Qing WangSemel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California 90095.
Anna KarydasMemory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, California 94158.
Suzee E LeeMemory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, California 94158.
Virginia E SturmMemory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, California 94158.ORCID 0000-0002-1717-298X
Russell P SawyerDepartment of Neurology and Rehabilitation Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267.
Adit FriedbergMemory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, California 94158.
Justin K IchidaDepartment of Stem Cell Biology and Regenerative Medicine, Keck School of Medicine of USC, University of Southern California, Los Angeles, California 90033.
Aaron D GitlerDepartment of Genetics, Stanford University School of Medicine, Stanford, California 94305.
Leo SugrueDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California 94158.
Michael CordingleyTransposon Therapeutics, San Diego, California 92122.
Walter BeeTransposon Therapeutics, San Diego, California 92122.
Eckard WeberTransposon Therapeutics, San Diego, California 92122.
Joel H KramerMemory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, California 94158.
Katherine P RankinMemory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, California 94158.
Howard J RosenMemory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, California 94158.
Adam L BoxerMemory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, California 94158.
William W SeeleyMemory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, California 94158.
John RavitsDepartment of Neurosciences, ALS Translational Research, University of California, San Diego, La Jolla, California 92093.
Bruce L MillerMemory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, California 94158.ORCID 0000-0002-2152-4220
Jennifer S YokoyamaMemory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, California 94158 jennifer.yokoyama@ucsf.edu.
University of California, San Francisco · USFate Therapeutics (United States) · USUniversity of California, Los Angeles · USStanford University · USUniversity of California San Diego · USUniversity of Cincinnati Medical Center · USUniversity of Southern California · US

Funding

Technology and Remote Assessment CoreU19AG063911 · NIA · MAYO CLINIC ROCHESTER · PI ADAM L. BOXER, Bradley F Boeve · 2019 to 2026
$120.9M
TDP-43 Loss-of-Function: Biology to BiomarkersP01AG019724 · NIA · UNIVERSITY OF PENNSYLVANIA · PI Jennifer Merrilees · 2002 to 2026
$67.2M
Research Education ComponentP30AG062422 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Gil Dan Rabinovici · 2019 to 2026
$36.9M
The Four Repeat Tauopathy Neuroimaging InitiativeR01AG038791 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BOXER, ADAM L. · 2010 to 2020
$18.1M
Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects (LEFFTDS)U01AG045390 · NIA · MAYO CLINIC ROCHESTER · PI BOEVE, BRADLEY F, ROSEN, HOWARD J · 2014 to 2018
$16.9M
Tau Metabolism in FTD: From Gene Mutations to Molecular Chaperones and Lysosomal ProteasesU54NS123985 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KARCH, CELESTE MARIE · 2021 to 2025
$9.0M
Emotion network dysfunction and decline in early frontotemporal dementiaR01AG052496 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Virginia Emily Sturm · 2017 to 2026
$6.9M
US-South American Initiative for Genetic-Neural-Behavioral Interactions in Human Neurodegenerative ResearchR01AG057234 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Claudia Duran-Aniotz, Agustin M. Ibanez · 2019 to 2026
$6.1M
Neurodevelopment in children from families with genetic frontotemporal dementia and Alzheimer’s diseaseR01AG071756 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SUZEE EURIE LEE · 2022 to 2026
$4.1M
Elucidating clinical heterogeneity in early-onset AD via genomics, transcriptomics, and neuroimagingR01AG062588 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI YOKOYAMA, JENNIFER S · 2019 to 2023
$4.0M
Veri-T: A phase 1 Placebo-Controlled Trial of Verdiperstat in Semantic Variant Primary Progressive Aphasia Due to Underlying FTLD-TDPR01AG073482 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ADAM L. BOXER, Peter Alexander Ljubenkov · 2021 to 2026
$3.3M
Defining trajectories of dynamic biomarkers for C9ORF72 repeat expansion carriersR01AG058233 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LEE, SUZEE EURIE · 2018 to 2022
$3.2M
NIA NIH HHS K01 AG049152NIA NIH HHS K24 AG045333NIA NIH HHS P01 AG019724NIA NIH HHS P30 AG062422NIA NIH HHS R01 AG038791NIA NIH HHS R01 AG052496NIA NIH HHS R01 AG057234NIA NIH HHS R01 AG058233NIA NIH HHS R01 AG062588NIA NIH HHS R01 AG071756NIA NIH HHS R01 AG073482NIA NIH HHS U01 AG045390NIA NIH HHS U19 AG063911NINDS NIH HHS U54 NS123985
6 · The paper itself

Abstract

Hexanucleotide repeat expansion (HRE) within

Indexed as

Amyotrophic Lateral SclerosisFrontotemporal DementiaAtrophyC9orf72 ProteinDNA Transposable ElementsFemaleHumansMaleC9orf72 ProteinC9orf72 protein, humanDNA Transposable ElementsC9orf72dementianeurodegenerationradiogenomicsthalamustransposable elements

Identifiers

PMID36446586
PMCPMC9838702
OpenAlexW4310352345

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.